Bristol-Myers Squibb stock, buy signal in its 5th week
Bristol-Myers Squibb stock: +5% since entry, knocking on the highs
Our view last week
Bristol-Myers Squibb stock slips 1.4% this week, continuing last week's early fatigue signs. Our weekly technical analysis still reads a solid picture: the ADX climbs to 26.4 and the trend gains conviction, while the latest bar shows only a slight edge for sellers. The buy signal, now in its 4th week, remains up 5% since entry - but the price is hugging the highs, with little room to run before the next historical resistance.
This week's summary
Bristol-Myers Squibb stock is back near its weekly highs, and the trend is gaining conviction: the weekly ADX has been climbing for six weeks and the price now sits above the 50-week average. The buy signal is in its 5th week, up 5% since entry, but buyers are showing early fatigue as the stock approaches a level already tested several times before.
IQS Phase
82
in tension / maturity
Signal Strength
47
medium · weak
Sizing
REDUCED
Ranking
#94 / 167
US stocks in progress
Trade P&L %
+10.32%
from signal to date, no stop loss
Rank position
ranks 94th among the 167 Longs already running for US stocks in our ranking, with a signal strength of 47 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein strong phase
Performanceweekly +4.33% · monthly +9.53%
BMY belongs to the health care sector (reference ETF XLV). The sector is classified in strong phase according to our weekly reading.
restricted Platinum content